Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.


PINL:GRPOF - Post by User

Comment by equity4481on May 14, 2021 1:47pm
381 Views
Post# 33204388

RE:RE:Enrollment

RE:RE:EnrollmentI reached out to Media at TBP and Natalie advises the following:

Thank you for contacting Tetra. I trust this email finds you well.

 

I confirm, as stated in the Press Release of May 6, that the REBORN1 trial has started.

 

A separate Press Release, which was launched on May 11 regarding Tetra’s other clinical trial (PLENITUDE), announced the acceleration of the enrolment activities. The vaccination campaign has reduced the impact of the pandemic on hospitals which allows us to now accelerate enrolment. This trial began in September 2020 and is ongoing. Link below for your awareness.

 

https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2021/Tetra-Bio-Pharma-Accelerates-PLENITUDEC-Clinical-Trial-to-Evaluate-the-Effect-of-Cannabis-for-Use-in-Managing-Uncontrolled-Cancer-Pain/default.aspx

 

Kindest regards,

Natalie

<< Previous
Bullboard Posts
Next >>